Treatment of cryptosporidiosis

Expert Review of Anti-Infective Therapy

Volumn 7, Issue 4, 2009, Pages 385-391

  Pantenburg, Birte ^a   Cabada, Miguel M ^a   White Jr , A Clinton ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETORPHAN; ANTIPARASITIC AGENT; ANTIRETROVIRUS AGENT; AZITHROMYCIN; INDINAVIR; NELFINAVIR; NITAZOXANIDE; OCTREOTIDE; PAROMOMYCIN; PLACEBO; PROTEINASE INHIBITOR; RIFABUTIN; RIFAXIMIN; RITONAVIR; SAQUINAVIR; SOMATOSTATIN; COCCIDIOSTATIC AGENT; RIFAMYCIN; THIAZOLE DERIVATIVE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CHOLECYSTECTOMY; CLINICAL FEATURE; CLINICAL TRIAL; CRYPTOSPORIDIOSIS; DIARRHEA; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; EDITORIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOCOMPROMISED PATIENT; MALNUTRITION; NONHUMAN; NUTRITIONAL SUPPORT; PROGNOSIS; AIDS RELATED COMPLEX; ANIMAL; BILIARY TRACT DISEASE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; IMMUNE DEFICIENCY; IMMUNOLOGY;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANIMALS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; AZITHROMYCIN; BILIARY TRACT DISEASES; COCCIDIOSTATS; CRYPTOSPORIDIOSIS; HUMANS; IMMUNOCOMPROMISED HOST; PAROMOMYCIN; RIFAMYCINS; THIAZOLES;

EID: 67650139060     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/ERI.09.24     Document Type: Editorial

References (64)

1. Guerrant DI, Moore SR, Lima AA, Patrick PD, Schorling JB, Guerrant RL. Association of early childhood diarrhea and cryptosporidiosis with impaired physical fitness and cognitive function four - seven years later in a poor urban community in northeast Brazil. Am. J. Trop. Med. Hyg. 61(5), 707-713 (1999).
2. Checkley W, Gilman RH, Epstein LD et al. Asymptomatic and symptomatic cryptosporidiosis: their acute effect on weight gain in Peruvian children. Am. J. Epidemiol. 145(2), 156-163 (1997).
3. Molbak K, Hojlyng N, Gottschau A et al. Cryptosporidiosis in infancy and childhood mortality in Guinea Bissau, west Africa. BMJ 307(6901), 417-420 (1993).
4. Nair P, Mohamed JA, DuPont HL et al. Epidemiology of cryptosporidiosis in North American travelers to Mexico. Am. J. Trop. Med. Hyg. 79(2), 210-214 (2008).
5. Yoder JS, Hlavsa MC, Craun GF et al. Surveillance for waterborne disease and outbreaks associated with recreational water use and other aquatic facility-associated health events - United States, 2005-2006. MMWR Surveill. Summ. 57(9), 1-29 (2008).
6. Coutinho BP, Oria RB, Vieira CM et al. Cryptosporidium infection causes undernutrition and, conversely, weanling undernutrition intensifies infection. J. Parasitol. 94(6), 1225-1232 (2008).
7. Guerrant RL, Oria RB, Moore SR, Oria. MO, Lima AA. Malnutrition as an enteric infectious disease with long-term effects on child development. Nutr. Rev. 66(9), 487-505 (2008).
8. Phillips AD, Thomas AG, Walker-Smith JA. Cryptosporidium, chronic diarrhoea and the proximal small intestinal mucosa. Gut 33(8), 1057-1061 (1992).
9. Bushen OY, Davenport JA, Lima AB et al. Diarrhea and reduced levels of antiretroviral drugs: improvement with glutamine or alanyl-glutamine in a randomized controlled trial in northeast Brazil. Clin. Infect. Dis. 38(12), 1764-1770 (2004).
10. Carneiro-Filho BA, Bushen OY, Brito GA, Lima AA, Guerrant RL. Glutamine analogues as adjunctive therapy for infectious diarrhea. Curr. Infect. Dis. Rep. 5(2), 114-119 (2003).
11. Lima NL, Soares AM, Mota RM, Monteiro HS, Guerrant RL, Lima AA. Wasting and intestinal barrier function in children taking alanyl-glutamine-supplemented enteral formula. J. Pediatr. Gastroenterol. Nutr. 44(3), 365-374 (2007).
12. Sharpstone D, Neild P, Crane R et al. Small intestinal transit, absorption, and permeability in patients with AIDS with and without diarrhoea. Gut 45(1), 70-76 (1999).
13. Brantley RK, Williams KR, Silva TM et al. AIDS-associated diarrhea and wasting in Northeast Brazil is associated with subtherapeutic plasma levels of antiretroviral medications and with both bovine and human subtypes of Cryptosporidium parvum. Braz. J. Infect. Dis. 7(1), 16-22 (2003).
14. Garcia Compean D, Ramos Jimenez J, Guzman de la Garza F et al. Octreotide therapy of large-volume refractory AIDS-associated diarrhea: a randomized controlled trial. AIDS 8(11), 1563-1567 (1994).
15. Simon DM, Cello JP, Valenzuela J et al. Multicenter trial of octreotide in patients with refractory acquired immunodeficiency syndrome-associated diarrhea. Gastroenterology 108, 1753-1760 (1995).
16. Beaugerie L, Baumer P, Chaussade S et al. Treatment of refractory diarrhoea in AIDS with acetorphan and octreotide: a randomized crossover study. Eur. J. Gastroenterol. Hepatol. 8(5), 485-489 (1996).
17. Abubakar I, Aliyu S, Arumugam C, Hunter P, Usman N. Prevention and treatment of cryptosporidiosis in immunocompromised patients. Cochrane Database Syst. Rev. 1, CD004932 (2007).
18. Amadi B, Mwiya M, Musuku J et al. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Lancet 360(9343), 1375-1380 (2002).
19. Rossignol JF, Kabil SM, el-Gohary Y, Younis AM. Effect of nitazoxanide in diarrhea and enteritis caused by Cryptosporidium species. Clin. Gastroenterol. Hepatol. 4(3), 320-324 (2006).
20. Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study or Nitazoxanide. J. Infect. Dis. 184(1), 103-106. (2001).
21. Doumbo O, Rossignol JF, Pichard E et al. Nitazoxanide in the treatment of cryptosporidial diarrhea and other intestinal parasitic infections associated with acquired immunodeficiency syndrome in tropical Africa. Am. J. Trop. Med. Hyg. 56(6), 637-639. (1997).
22. Rossignol JF, Hidalgo H, Feregrino M et al. A double-blind placebo-controlled study of nitazoxanide in the treatment of cryptosporidial diarrhoea in AIDS patients in Mexico. Trans. R. Soc. Trop. Med. Hyg. 92(6), 663-666 (1998).
23. Hashmey R, Smith NH, Cron S, Graviss EA, Chapped CL, White AC Jr. Cryptosporidiosis in Houston, Texas. A report of 95 cases. Medicine 76, 118-139 (1997).
24. Stockdale HD, Spencer JA, Blagburn BL. Prophylaxis and chemotherapy. In: Cryptosporidium and Cryptosporidiosis. Fayer R, Xiao L (Eds). CRC Press, FL, USA 255-287 (2008).
25. Blanshard C, Shanson DC, Gazzard BG. Pilot studies of azithromycin, letrazuril, and paromomycin in the treatment of cryptosporidiosis. Int. J. STD AIDS 8, 124-129 (1997).
26. White AC Jr, Chappell CL, Hayat CS, Kimball KT, Flanigan TP, Goodgame RW. Paromomycin for cryptosporidiosis in AIDS: a prospective, double-blind trial. J. Infect. Dis. 170, 419-424 (1994).
27. Hewitt RG, Yiannoutsos CT, Higgs ES et al. Paromomycin: no more effective than placebo for treatment of cryptosporidiosis in patients with advanced human immunodeficiency virus infection. Clin. Infect. Dis. 31(4), 1084-1092 (2000).
28. White AC Jr, Cron SG, Chappell CL. Paromomycin in cryptosporidiosis. Clin. Infect. Dis. 32(10), 1516-1517 (2001).
29. White AC Jr, Goodgame RW, Chappell CL. Paromomycin for cryptosporidiosis in AIDS - reply [letter]. J. Infect. Dis. 171, 1071 (1995).
30. + count so important? Clin. Infect. Dis. 33(9), 1609-1611 (2001).
31. Hicks P, Zwiener RJ, Squires J, Savell V. Azithromycin therapy for Cryptosporidium parvum infection in four children infected with human immunodeficiency virus. J. Pediatr. 129(2), 297-300 (1996).
32. Trad O, Jumaa P, Uduman S, Nawaz A. Eradication of Cryptosporidium in four children with acute lymphoblastic leukemia. J. Trop. Pediatr. 49(2), 128-130 (2003).
33. Kadappu KK, Nagaraja MV, Rao PV, Shastry BA. Azithromycin as treatment for cryptosporidiosis in human immunodeficiency virus disease. J. Postgrad. Med. 48(3), 179-181 (2002).
34. Allam AF, Shehab AY. Efficacy of azithromycin, praziquantel and mirazid in treatment of cryptosporidiosis in school children. J. Egypt Soc. Parasitol. 32(3), 969-978 (2002).
35. Blagburn BL, Soave R. Prophylaxis and chemotherapy: human and animal. In: Cryptosporidium and Cryptosporidiosis. Fayer R (Ed.). CRC Press, FL, USA 111-128 (1997).
36. Meamar AR, Rezaian M, Rezaie S et al. Cryptosporidium parvum bovine genotype oocysts in the respiratory samples of an AIDS patient: efficacy of treatment with a combination of azithromycin and paromomycin. Parasitol. Res. 98(6), 593-595 (2006).
37. Palmieri F. Cicalini S. Froio N et al. Pulmonary cryptosporidiosis in an AIDS patient: successful treatment with paromomycin plus azithromycin. Int. J. STD AIDS 16(7), 515-517 (2005).
38. Nachbaur D, Kropshofer G, Feichtinger H, Allerberger F, Niederwieser D. Cryptosporidiosis after CD34-selected autologous peripheral blood stem cell transplantation (PBSCT). Treatment with paromomycin, azithromycin and recombinant human interleukin-2. Bone Marrow Transplant. 19(12), 1261-1263 (1997).
39. Smith NH, Cron S, Valdez LM, Chappell CL, White AC Jr. Combination drug therapy for cryptosporidiosis in AIDS. J. Infect. Dis. 178(3), 900-903 (1998).
40. Amenta M, Dalle Nogare ER, Colomba C et al. Intestinal protozoa in HIV-infected patients: effect of rifaximin in Cryptosporidium parvum and Blastocystis hominis infections. J. Chemother. 11(5), 391-395 (1999).
41. Gathe JC Jr, Mayberry C, Clemmons J, Nemecek J. Resolution of severe cryptosporidial diarrhea with rifaximin in patients with AIDS. J. Acquir. Immune Defic. Syndr. (1999), 48(3), 363-364 (2008).
42. Holmberg SD, Moorman AC, Von Bargen JC et al. Possible effectiveness of clarithromycin and rifabutin for cryptosporidiosis chemoprophylaxis in HIV disease. HIV Outpatient Study (HOPS) Investigators. JAMA 279(5), 384-386 (1998).
43. Fichtenbaum CJ, Zackin R, Feinberg J, Benson C, Griffiths JK. Rifabutin but not clarithromycin prevents cryptosporidiosis in persons with advanced HIV infection. AIDS 14(18), 2889-2893 (2000).
44. Blanshard C, Jackson AM, Shanson DC, Francis N, Gazzard BG. Cryptosporidiosis in HIV-seropositive patients. Q. J. Med. 85(307-308), 813-823 (1992).
45. Babiker A, Darbyshire J, Pezzotti P et al. Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. Int. J. Epidemiol. 31(5), 951-958 (2002).
46. 3. Am J. Gastroenterol. 95(11), 3142-3146 (2000).
47. Le Moing V, Bissuel F, Costagliola D et al. Decreased prevalence of intestinal cryptosporidiosis in HIV-infected patients concomitant to the widespread use of protease inhibitors. AIDS 12(11), 1395-1397 (1998).
48. Grube H, Ramratnam B, Ley C, Flanigan TP. Resolution of AIDS associated cryptosporidiosis after treatment with indinavir. Am J. Gastroenterol. 92(4), 726 (1997).
49. Bobin S, Bouhour D, Durupt S, Boibieux A, Girault V, Peyramond D. [Importance of antiproteases in the treatment of microsporidia and/or cryptosporidia infections in HIV-seropositive patients]. Pathol. Biol. 46(6), 418-419 (1998).
50. Foudraine NA, Weverling GJ, van Grool T et al. Improvement of chronic diarrhea in patients with advanced HIV-1 infection during potent antiretroviral therapy. AIDS 12, 35-41 (1998).
51. Miao YM, Awad-El-Kariem FM, Franzen C et al. Eradication of cryptosporidia and microsporidia following successful antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 25(2), 124-129 (2000).
52. Maggi P, Larocca AM, Quarto M et al. Effect of antiretroviral therapy on cryptosporidiosis and microsporidiosis in patients infected with human immunodeficiency virus type 1. Eur. J. Clin. Microbiol. Infect. Dis. 19(3), 213-217 (2000).
53. Carr A, Marriott D, Field A, Vasak E, Cooper DA. Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy. Lancet 351, 256-261 (1998).
54. Okhuysen PC, Robinson P, Nguyen MT et al. Jejunal cytokine response in AIDS patients with chronic cryptosporidiosis and during immune reconstitution. AIDS 15(6), 802-804 (2001).
55. Miao YM, Awad-El-Kariem FM, Gibbons CL, Gazzard BG. Cryptosporidiosis: eradication or suppression with combination antiretroviral therapy? AIDS 13(6), 734-735 (1999).
56. Forney JR, Yang S, Du C, Healey MC. Efficacy of serine protease inhibitors against Cryptosporidium parvum infection in a bovine fallopian tube epithelial cell culture system. J. Parasitol. 82(4), 638-640 (1996).
57. Kniel KE, Sumner SS, Pierson MD et al. Effect of hydrogen peroxide and other protease inhibitors on Cryptosporidium parvum excystation and in vitro development. J. Parasitol. 90(4), 885-888 (2004).
58. Morales Gomez MA. [Highly active antiretroviral therapy and cryptosporidiosis]. Parassitologia 46(1-2), 95-99 (2004).
59. Mele R, Gomez Morales MA, Tosini F, Pozio E. Indinavir reduces Cryptosporidium parvum infection in both in vitro and in vivo models. Int. J. Parasitol. 33(7), 757-764 (2003).
60. Hommer V, Eichholz J, Petry F. Effect of antiretroviral protease inhibitors alone, and in combination with paromomycin, on the excystation, invasion and in vitro development of Cryptosporidium parvum. J. Antimicrob. Chemother. 52(3), 359-364 (2003).
61. French AL, Beaudet LM, Benator DA, Levy CS, Kass M, Orenstein JM. Cholecystectomy in patients with AIDS - clinicopathologic correlations in 107 cases. Clin. Infect. Dis. 21, 852-858 (1995).
62. Bouche H, Housset C, Dumont JL et al. AIDS-related cholangitis: diagnostic features and course in 15 patients. J. Hepatol. 17(1), 34-39 (1993).
63. Cordero E, Lopez-Cortes LF, Belda O, Villanueva JL, Rodriguez-Hernandez MJ, Pachon J. Acquired immunodeficiency syndrome-related cryptosporidial cholangitis: resolution with endobiliary prosthesis insertion. Gastrointest. Endosc. 53(4), 534-535 (2001).
64. Yusuf TE, Baron TH. AIDS Cholangiopathy. Curr. Treat. Options Gastroenterol. 7(2), 111-117 (2004).